BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026.
Upcoming Investor Conferences:
Bank of America Health Care Conference 2026:
Date: Tuesday, May 12, 2026
Fireside Chat: 3:40 – 4:10 PM PDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Las Vegas, NV
Stifel 2026 Virtual Ophthalmology Forum:
Date: Tuesday, May 26, 2026
Fireside Chat: 2:30 – 2:55 PM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual
A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.
Upcoming Scientific Conferences:
Eyecelerator @ ARVO 2026: May 1, 2026
Denver, CO
- Presentation: Ocular Therapeutix: Retina Experience Redefined
Presentation Date/Time: Friday, May 1, 2026, 2:18 – 2:23 PM MDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix
ARVO 2026 Annual Meeting: May 3 - 7, 2026
Denver, CO
- Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Phase 3 SOL-1 Trial Results
Presentation Date/Time: Tuesday, May 5, 2026, 1:15 – 1:30 PM MDT
Presenter: Patricio G. Schlottmann, MD
- Poster Title: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database
Session Date/Time: Thursday, May 7, 2026, 8:00 – 9:45 AM MDT
Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS
- Poster Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry
Session Date/Time: Thursday, May 7, 2026, 8:00 – 9:45 AM MDT
Presenter: Christina Y. Weng, MD, MBA
Retina World Congress (RWC) 2026: May 14 - 17, 2026
Fort Lauderdale, FL
- Presentation Title: Ocular Therapeutix: Retina Experience Redefined
Presentation Date/Time: Thursday, May 14, 2026, 8:15 – 8:20 AM EDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix
- Presentation Title: Update on Latest TKI data from the OTX-TKI program
Presentation Date/Time: Friday, May 15, 2026, 4:30 – 4:35 PM EDT
Presenter: Dilsher S. Dhoot, MD
- Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
Symposium Date/Time: Friday, May 15, 2026, 7:15 – 8:15 PM EDT
Presenters: Patricio G. Schlottmann, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD
The Royal College of Ophthalmologists Annual Congress 2026: May 18 - 20, 2026
Manchester, UK
- Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
Symposium Date/Time: Tuesday, May 19, 2026, 12:30 – 1:30 PM BST
Presenters: Adnan Tufail, MBBS, MD, FRCOphth; Darius M. Moshfeghi, MD; Dilsher S. Dhoot, MD
Exact medical conference presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]